Navan is capturing enterprise T&E share with 30%-plus growth, AI-driven margin expansion, and positive FCF, but its premium valuation, heavy SBC, and high execution expectations leave little room for disappointment.
Sell-rated reports
287 tickers rated SellDiageo's powerful global beverage brands and restructuring savings offer turnaround potential, but sustained U.S. spirits weakness, elevated leverage, and reduced near-term cash flow limit investment appeal.
OUTFRONT Media benefits from scarce advertising locations, rising digital monetization, and improving cash flow, but a premium historical valuation, significant leverage, and cyclical advertising demand constrain its investment appeal.
Viatris generates substantial free cash flow and is transitioning toward higher-value medicines, but manufacturing disruptions, acquisition execution risk and substantial historical valuation expansion limit its current investment appeal.
Qualcomm's wireless patents, automotive growth, and emerging AI data-center business offer long-term upside, but falling handset sales, squeezed margins, and weaker free cash flow undermine the near-term investment case.
LandBridge owns scarce Permian Basin acreage that generates high-margin recurring royalties and offers digital infrastructure upside, but demanding valuation and acquisition-related leverage constrain its investment appeal.
Medline's integrated medical-surgical distribution network and strong organic growth provide durable expansion potential, but margin pressure, leverage, and a demanding valuation constrain its near-term investment appeal.
Royalty Pharma offers a scalable pharmaceutical royalty franchise with strong cash generation and reinvestment opportunities, but its historically elevated valuation, finite royalty lives, and leverage weaken the current risk-reward balance.
Takeda's established specialty medicines, recovering profitability, and shareholder dividends support long-term cash generation, but patent erosion, soft underlying growth, and an elevated historical cash-flow multiple limit investment appeal.
Belden offers exposure to industrial automation, enterprise networking, and data center infrastructure growth, but acquisition-driven leverage and uncertain RUCKUS integration returns constrain its near-term investment appeal.
LKQ's global aftermarket distribution network and low valuation offer recovery potential, but severe European execution failures, declining earnings, and withdrawn guidance undermine confidence in a sustainable turnaround.
CRH owns a durable network of construction-materials assets positioned for long-term infrastructure demand, but weakening margins, elevated acquisition commitments, and uncertain near-term cash-flow growth constrain its investment appeal.